SCHEMBL4287293

SCHEMBL4287293

O=C(O)CCC(=O)Nc1cccc(-c2c[nH]c(=O)c3c2ccc2ccc(Cl)cc23)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
IGF1R P08069 2/20 0.43
GFER P55789 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP1A2 P05177 2/20 0.41
GSK3B P49841 1/20 0.40
PTPN11 Q06124 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HSD17B1 P14061 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B2 P37059 1/20 0.39
PARP1 P09874 1/20 0.38
POLB P06746 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
F2R P25116 1/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288022 0.89 ROCK2 (0.46) ALDH1A1CYP1A2GSK3BCYP3A4CYP2D6
SCHEMBL13662591 0.89 RAB9A (0.45) ALDH1A1IGF1RMEN1KMT2ACYP1A2
SCHEMBL4295944 0.85 SMN1; SMN2 (0.45) IGF1RMEN1KMT2AHSD17B1HSD17B2
SCHEMBL4287646 0.80 SERPINE1 (0.45) CYP2C9PARP1
SCHEMBL4287635 0.78 PARP1 (0.55) ALDH1A1MEN1KMT2AGSK3BPARP1
SCHEMBL4287632 0.78 CHEK1 (0.45) PARP1
SCHEMBL4294755 0.77 CHEK1 (0.44) GSK3BPARP1KDR
SCHEMBL4291937 0.73 MAP2K4 (0.47) PARP1SMN1; SMN2KDM4E
SCHEMBL4296952 0.72 CHEK1 (0.44) KDM4E
SCHEMBL4293948 0.72 MAPK8 (0.47) IGF1RKMT2APARP1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US claimed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A ALDH1A1 2405/4885IGF1R 1142/4885GFER 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.